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http://www.molecular-cancer.com/content/13/1/209RESEARCH Open AccessSurvivin expression promotes VEGF-induced
tumor angiogenesis via PI3K/Akt enhanced
β-catenin/Tcf-Lef dependent transcription
Jaime G Fernández1,2, Diego A Rodríguez1,3, Manuel Valenzuela1,8, Claudia Calderon1,8, Ulises Urzúa4,
David Munroe5, Carlos Rosas6, David Lemus6, Natalia Díaz1, Mathew C Wright7, Lisette Leyton1, Julio C Tapia4
and Andrew FG Quest1,8*Abstract
Early in cancer development, tumour cells express vascular endothelial growth factor (VEGF), a secreted molecule
that is important in all stages of angiogenesis, an essential process that provides nutrients and oxygen to the
nascent tumor and thereby enhances tumor-cell survival and facilitates growth. Survivin, another protein involved
in angiogenesis, is strongly expressed in most human cancers, where it promotes tumor survival by reducing
apoptosis as well as favoring endothelial cell proliferation and migration. The mechanisms by which cancer cells
induce VEGF expression and angiogenesis upon survivin up-regulation remain to be fully established. Since the
PI3K/Akt signalling and β-catenin-Tcf/Lef dependent transcription have been implicated in the expression of many
cancer-related genes, including survivin and VEGF, we evaluated whether survivin may favor VEGF expression,
release from tumor cells and induction of angiogenesis in a PI3K/Akt-β-catenin-Tcf/Lef-dependent manner. Here, we
provide evidence linking survivin expression in tumor cells to increased β-catenin protein levels, β-catenin-Tcf/Lef
transcriptional activity and expression of several target genes of this pathway, including survivin and VEGF, which
accumulates in the culture medium. Alternatively, survivin downregulation reduced β-catenin protein levels and
β-catenin-Tcf/Lef transcriptional activity. Also, using inhibitors of PI3K and the expression of dominant negative Akt,
we show that survivin acts upstream in an amplification loop to promote VEGF expression. Moreover, survivin
knock-down in B16F10 murine melanoma cells diminished the number of blood vessels and reduced VEGF expression
in tumors formed in C57BL/6 mice. Finally, in the chick chorioallantoid membrane assay, survivin expression in
tumor cells enhanced VEGF liberation and blood vessel formation. Importantly, the presence of neutralizing
anti-VEGF antibodies precluded survivin-enhanced angiogenesis in this assay. These findings provide evidence
for the existance of a posititve feedback loop connecting survivin expression in tumor cells to PI3K/Akt enhanced
β-catenin-Tcf/Lef-dependent transcription followed by secretion of VEGF and angiogenesis.
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Angiogenesis is a physiological process characterized by
the generation of new blood vessels from preexisting ones.
In cancer biology, angiogenesis is required to permit in-
creased delivery of oxygen and nutrients to the nascent* Correspondence: aquest@med.uchile.cl
1Laboratorio de Comunicaciones Celulares, Centro de Estudios Moleculares
de la Célula (CEMC), Programa de Biología Celular y Molecular, ICBM,
Facultad de Medicina, Universidad de Chile, Santiago, Chile
8Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile
Full list of author information is available at the end of the article
© 2014 Fernández et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.tumor [1]. This process, whether physiological or patho-
logical, involves several steps, including release of extracel-
lular factors, endotheliocyte migration, proliferation and
formation of new vessels. Amongst all the molecules
participating in these events, vascular endothelial growth
factor (VEGF) is particularly relevant because it modulates
the function of vascular and non-vascular cells [2], and
promotes every step of angiogenesis, in both physiological
and pathological conditions [3].
In tumors, the inhibitor of apoptosis protein (IAP) sur-
vivin has been ascribed highly pleiotropic functions andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.molecular-cancer.com/content/13/1/209is associated with tumor progression, metastasis and
angiogenesis [4]. Importantly, survivin is overexpressed
in essentially all human cancers and generally absent in
normal adult tissues [5]. As part of the chromosomal
passenger complex, crucial for mitosis, survivin facili-
tates proliferation [6]. Also, as an IAP, this protein is im-
plicated in the inhibition of apoptosis, although the
mechanism by which this is achieved remains a matter
of debate. Some possibilities include interaction and
stabilization of the anti-apoptotic proteins XIAP [7]
or HBXIP [8] and inhibition of pro-apoptotic proteins
like second mitochondria-derived activator of caspases/
direct inhibitor of apoptosis binding protein with low pI
(SMAC/DIABLO) [9] or Apoptosis Inducing Factor (AIF)
[10]. More recently survivin has been shown to promote
invasion and metastasis by enhancing Nuclear Factor
kappa-light-chain-enhancer of activated B cells (NF-κB)-
dependent transcription of fibronectin [11].
Survivin has also been shown to promote survival of
endothelial cells (EC), EC proliferation and angiogenesis,
an expected finding given that proliferating EC need to
upregulate survivin [12,13]. Rather intriguingly, down
regulation of survivin in tumor cells and not in the EC
was also shown to reduce angiogenesis in gastric cancer
cell lines [14] suggesting that survivin may regulate
angiogenesis not only by controlling EC proliferation,
but also via mechanisms occurring in the tumor cells
that enhance angiogenesis. These findings have been
examined in human breast cancer and cervical cancer
cell lines [15], and more recently, survivin was shown
to favor angiogenesis by enhancing secretion of VEGF
[16]. Thus, despite clearly being relevant to the process
of angiogenesis, the mechanisms by which survivin
expression in tumor cells favors this process remain
poorly defined.
Survivin expression is regulated by transcriptional and
posttranslational events. Transcription factors implicated
in controlling survivin expression include Hypoxia Inducible
Factor 1α (HIF-1α, Specificity Protein 1 (Sp-1), NFκB, Signal
Transducer and Activator of Transcription 3 (STAT3), Notch
and β-catenin-Tcf/Lef [17,18].
The β-catenin-Tcf/Lef is one of the most studied path-
ways involved in regulating survivin. Although initially
described in drosophila development [19,20], the Wnt/
β-catenin signaling pathway was rapidly recognized to
play a critical role in human cancer [21,22]. For instance,
the adenomatous poliposis coli (APC) protein is part
of the complex involved in β-catenin degradation and
APC mutations or deletions are known causes of heredi-
tary colon cancer (Familial Adenomatous Polyposis coli
patients) [23]. In the absence of Wnt ligands, β-catenin
is phosphorylated and targeted for degradation by the
multi-protein complex that includes Glycogen Synthase
Kinase 3β (GSK-3β), APC, Axin, β-catenin, Casein Kinase1 and others [24,25]. When Wnts bind to their recep-
tors, the aforementioned multi-protein complex is
disassembled, β-catenin is no longer phosphorylated or
degraded, cytoplasmic levels increase and the protein
translocates to the nucleus where, together with Tcf/Lef
family members, transcription of many genes implicated
in development and progression of cancer are increased,
including survivin, COX-2, Cyclin D1, Runx-2 and
VEGF [26-30].
Interestingly, effectors downstream of β-catenin-Tcf/Lef
like COX-2 feedback into this pathway and enhance sig-
naling: a study in this respect provided evidence in colon
cancer cells showing that prostaglandin E2 (PGE2), a
product of COX-2 activity, promotes signaling events that
preclude β-catenin degradation [31]. Results from our la-
boratory have shown that caveolin-1 facilitates the process
of β-catenin recruitment to the membrane and thereby
precludes β-catenin-Tcf/Lef-dependent transcription of
survivin and COX-2 [32,33]. Rather intriguingly, PGE2
stimulation of colon cancer cells also disrupts the
plasma membrane complex containing E-cadherin/Cav-
eolin-1 responsible for sequestration of β-catenin [33].
Thus, outside-in signaling downstream of COX-2 blocks
pathways responsible for both the degradation and se-
questration of β-catenin, augmenting in this manner
βcatenin-Tcf/Lef dependent transcription of several
genes important in cancer cells.
Considering the importance of survivin in angiogenesis
and the general absence of molecular insight, we exam-
ined the possibility that in analogy to the COX2-PGE2
loop, survivin might feedback into the βcatenin/Tcf-Lef
pathway and thereby enhance expression of genes im-
portant for angiogenesis. Indeed, our studies show that
survivin increases β-catenin-Tcf/Lef transcriptional ac-
tivity, the expression of target genes, such as CyclinD1
or VEGF, vessel density in a mouse model and induces
angiogenesis in a VEGF-dependent manner in the chick
chorioallantoid membrane model. Importantly, these ef-
fects of survivin were shown to be mediated by activa-
tion of the PI3K/Akt pathway.
Results
To assess the effects of survivin on β-catenin protein
levels and transcriptional activity, HEK293T cells were
transfected with pEGFP-survivin or pcDNA-survivin and
their respective empty vector controls. Upon survivin
expression, a dose-dependent increase in β-catenin levels
was detected together with an increase in endogenous
survivin protein that was distinguishable from exogen-
ous GFP-survivin by virtue of its molecular weight
(Figure 1A,B). Additionally, as a positive control, β-catenin
levels increased in the presence of the GSK3-β inhibitor
SB216763 (Figure 1A-B). Because GSK3β activity pro-
motes proteasome-mediated degradation of β-catenin,
Figure 1 (See legend on next page.)
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Figure 1 Survivin expression increased endogenous survivin and β-catenin protein levels, as well as β-catenin/Tcf-Lef dependent
transcriptional activity: A,B: HEK293T cells (5×105) were transfected with pEGFP-C1 or pEGFP-survivin (A), pcDNA or pcDNA-survivin (B)
or treated with SB216763 (20 μM), a pharmacological inhibitor of GSK-3β. β-catenin, survivin and actin protein levels were evaluated by
western blotting. Protein levels were quantified by scanning densitometric analysis of western blots and normalized to actin. In panel A second lane, a
band reflecting GFP dimerization is also visible. C,D: HEK293T cells (5×105) were seeded in 6-well plates and transiently cotransfected with pEGFP-C1
(1.5 μg) or pEGFP-survivin (0.5-1.5 μg) and additionally with the reporter plasmids pLuc-1710 (intact survivin promoter, 1 μg) pLuc-3M (survivin promoter
with 2 TBEs mutated, 1 μg) (C), pTOP-FLASH (three functional TBEs in tandem) or pFOP-FLASH (all TBEs mutated, 1 μg each) (D). Luciferase activity was
obtained by calculating the pLuc 1710/pLuc 3M or the pTOP-FLASH/pFOP-FLASH activity ratios for each condition. Data were previously normalized to
values for β-galactosidase activity. E-H: NIH3T3 (E,F) cells (5×105) or MKN45 (G,H) cells (5×105) were seeded in 6-well plates and transiently transfected
with pEGFP-C1 or pEGFP-survivin (1 μg each). E-G: β-catenin, survivin, GFP and actin protein levels were evaluated by western bloting. F-H: cells were
cotransfected with pTOP-FLASH or pFOP-FLASH (1 μg) vectors and luciferase activity was obtained by calculating the pTOP-FLASH/pFOP-FLASH activity
ratios for each condition. Data were previously normalized to values for β-galactosidase activity. Numerical data shown are the means ± s.e.m. of results
obtained in three independent experiments. Statistically significant differences compared to mock controls are indicated (*p < 0.05).
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protein levels.
Next, the effect of survivin overexpression on β-catenin-
Tcf/Lef-dependent transcriptional activity was evaluated
using reporter assays for β-catenin-Tcf/Lef activity and a
survivin promoter-specific construct. In both cases, a dose
dependent increase was detected upon GFP-survivin
expression (Figure 1C,D). Subsequently, we evaluated
whether the observations in HEK293T cells were also de-
tectable in additional cell lines like mouse fibroblasts
(NIH3T3) and human gastric cancer cells (MKN45). For
both cell lines, increases in β-catenin protein levels and β-
catenin-Tcf/Lef transcriptional activity were observed
(Figure 1E-H). However, given the interest here in uncover-
ing a new role for survivin in cancer, we decided to focus
our subsequent characterization on the human gastric can-
cer cell line MKN45 in addition to the human embryonic
kidney HEK293T cells.
Accumulation of β-catenin in the nucleus promotes
the expression of a wide range of genes related to can-
cer. In an mRNA-based microarray study, HEK293T
cells expressing or not GFP-survivin were compared. A
noticeable increase in the relative expression of many
Wnt target-genes related to cancer was detectable in this
experiment (see Additional file 1: Supplementary infor-
mation 1). In this context, selected genes associated with
cancer were further characterized by RT-PCR. Increases
in Runx-2, COX-2 and CyclinD1 mRNA were detected
by semi-quantitative RT-PCR (Figure 2A) and by quanti-
tative qPCR (Figure 2B). Moreover, changes in mRNA
levels of the respective genes were found to lead to in-
creased expression of the respective proteins as revealed
Western blot analysis (Figure 2C). Likewise, in MKN45
gastric cancer cells, GFP-survivin expression also in-
creased significantly mRNA levels of these β-catenin/
Tcf-Lef target genes as evaluated by qPCR (Figure 2D).
Moreover, an increase in protein levels of endogenous
survivin, COX-2, and Cyclin D1 upon GFP-survivin
overexpression was detected in MKN-45 cells (Figure 2E)
upon analysis by Western Blotting.To confirm the relevance of these findings, the effect
of survivin down-regulation using shRNA technology
was evaluated in B16F10 mouse melanoma using virus-
mediated cell transduction. This cell line was chosen
because they were subsequently employed in tumor for-
mation experiments in syngeneic C57BL6 mice with an
intact immune system as previously described by our la-
boratory [34,35]. Also, because these cells already have
relatively high endogenous levels of survivin as com-
pared with others, further increases in survivin by over-
expression had little effect (data not shown). For these
reasons, we chose this cell line to implement the oppos-
ite approach, namely to downregulate survivin. Indeed,
shRNA targeting mouse survivin decreased survivin, β-
catenin, COX-2, Cyclin D1 protein levels (Figure 3A).
Moreover, β-catenin-Tcf/Lef-dependent transcriptional
activity decreased significantly upon survivin knock-
down in both shSUR1 and shSUR2 sublines when com-
pared to shLUC control cells (Figure 3B). Alternatively,
in ZR-75 human breast cancer cells shRNA-mediated
survivin knock-down was evaluated using a commer-
cially available plasmid that permitted selecting popula-
tions expressing shRNA against survivin or a scrambled
shRNA sequence. Again, both survivin and β-catenin
protein levels decreased in cells expressing the survivin-
specific sequence, but not in control cells (see Additional
file 1: Supplementary information 2).
To explore mechanisms that may explain how survivin
affects β-catenin/Tcf-Lef signalling, different pharmaco-
logical inhibitors were evaluated. Only PI3K inhibitors
were found to suppress the ability of survivin to aug-
ment β-catenin levels (see Additional file 1: Supplemen-
tary information 3). Specifically, the inhibitor LY294002
was shown to suppress the ability of GFP-survivin to in-
crease endogenous β-catenin and survivin protein levels
(Figure 4A). Interestingly, GFP-survivin overexpression
also increased the p-Akt/Akt ratio, suggesting activation
of the PI3K/Akt pathway, which is known to promote β-
catenin-Tcf/Lef dependent transcription (see Discussion).
To confirm the role of PI3K, Wortmannin, a well-established
Figure 2 Survivin expression increased mRNA and protein levels of β-catenin/Tcf-Lef target genes: A,B: HEK293T cells (5 × 105) were
seeded in 6-well plates and transfected with pEGFP-C1 or pEGFP-survivin (1.5 μg). A: After 24 h Cyclin D1, Runx-2, COX-2 and survivin
mRNA levels were assessed by semi-quantitative RT-PCR. Actin was used as an internal control B: Runx-2,COX-2 and Cyclin D1 mRNA levels were
assessed by qPCR. Ribosomal 18S RNA was used as an internal control. Relative Units (RU) reflect normalization to controls. Values are means of
results obtained in three independent experiments. Statistically significant differences compared to mock-transfected controls are indicated
(* p < 0.05). C: Cyclin D1, COX-2 and endogenous survivin levels were evaluated by western blotting. Actin was used as an internal control.
Expression of GFP and GFP-survivin in the respective lanes was revealed with a GFP-specific antibody. D, E: Wild type MKN45 gastric cancer cells
(5×105) were seeded in 6-well plates and transfected with with pEGFP-C1 or pEGFP-survivin (1.5 μg). After 24 h mRNA and protein levels were
assessed by qPCR and western blotting, respectively. D: Runx-2, COX-2 and cyclin D1 mRNA levels were assessed by qPCR. Ribosomal 18S RNA
was used as an internal control. Relative Units (RU) reflect normalization to controls. Values are means of results obtained in three independent
experiments. Statistically significant differences compared to mock-transfected controls are indicated (* p < 0.05). E: Cyclin D1, COX-2 and
endogenous survivin protein levels were evaluated by western blotting, quantified by scanning densitometry of immunoblots and normalized to
actin. Numerical data shown are means of results obtained in three independent experiments. Statistically significant differences compared to
mock controls are indicated (* p < 0.05).
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mediated increases in endogenous β-catenin and survivin
expression (Figure 4B). Moreover, the effects of expressing
a dominant negative Akt variant were evaluated. Here, we
used a pcDNA-survivin plasmid because pEGFP-survivin
together with the genetic inhibitor decreased cell viability.
Dominant negative Akt suppressed the effects of survivin
on β-catenin protein levels (Figure 4C). Finally, β-catenin-
Tcf/Lef reporter activity was assessed upon LY294002
treatment and expression of dominant negative Akt.In both cases, the ability of survivin to enhance β-
catenin-Tcf/Lef transcriptional activity was suppressed
(Figure 4D,E).
To explore the relationship between survivin and
angiogenesis, we focused first on evaluating VEGF
expression, a target of β-catenin-Tcf/Lef. An increase in
VEGF mRNA expression had previously been detected
by microarray analysis following GFP-survivin overexpres-
sion (see Additional file 1: Supplementary information 1).
Hence, changes in VEGF mRNA variants were evaluated
Figure 3 Survivin downregulation decreased β-catenin protein
levels and β-catenin/Tcf-Lef transcriptional activity: A,B: B16F10
cells were stably transfected with 2 different shRNA targeting
mouse survivin (shSUR1 and shSUR2) or luciferase (shLUC) as a
control. Batch populations of cells (5×105) were seeded in 6-wells
plates A: After 24 h, β-catenin, COX-2, Cyclin D1, survivin, and actin
protein levels were evaluated by western blotting. Protein levels were
quantified by scanning densitometric analysis of western blots and
normalized to actin. Numerical data shown are the means of results
obtained in three independent experiments. Statistically significant
differences compared to shLUC controls are indicated (* p < 0.05). B:
B16F10 (shLUC, shSUR1 and shSUR2) cells were transiently transfected
with the reporter plasmids pTOP-FLASH or pFOP-FLASH (1 μg). Luciferase
activity was obtained by calculating the pTOP-FLASH/pFOP-FLASH
activity ratios for each condition. Data were previously normalized to
values for β-galactosidase activity. Numerical data shown are the means
± s.e.m. of results obtained in three independent experiments. Statistically
significant differences between shSUR1-2 and shLUC controls are
indicated (* p < 0.05).
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Indeed, VEGF165 increased under these conditions as
observed by semiquantitative RT-PCR (Figure 5A) and
quantitative PCR (Figure 5B). Moreover, VEGF levels
in the culture medium increased upon GFP-survivinoverexpression in HEK293T and MKN45 as detected
using an ELISA assay (Figure 5C,D).
Further, the in vivo role of survivin in cancer cells
was evaluated using cells stably transfected with shLUC
and shSUR2 (Figure 3A). C57BL6 mice were subcutane-
ously injected with these cells and tumors were allowed
to grow to the same volume in all cases. Histological
analysis revealed that tumours derived from shLUC-
transfected cells had more vessels than those formed by
shSUR2-transfected cells (Figure 6A photographs).
Average blood vessel quantification expressed as
microvessel density corroborates these observations
(Figure 6A, graph). Also, immunohistochemical analysis
with an antibody directed against VEGF revealed de-
creased VEGF expression in tumours derived from
shLUC-transfected cells (Figure 6B, photographs).
Quantification of VEGF-specific staining corroborates
these findings (Figure 6B, graph).
Finally, the effect of survivin overexpression was evalu-
ated in an in-vivo model of angiogenesis using the chicken
chorioallantoic membrane assay (Chick-CAM assay). To
this end, either supernatants from HEK293T cells trans-
fected with pEGFP or pEGFP-survivin collected after 48 h
or the cells themselves were applied to chorioallantoic
membranes and evaluated. Both pEGFP-survivin-transfected
HEK293T cells and supernatants from the same cells in-
creased the number of blood vessels in the CAM assays
(Figure 7A,B). Importantly, the effect of supernatants
from EGFP-survivin expressing cells on angiogenesis
was abolished in the presence of specific neutralizing
antibodies against VEGF in a specific manner, because
treatment with unrelated antibodies (β-3 antibody, nega-
tive control) were not able to suppress the GFP-survivin
effect (Figure 7C).
Discussion
Survivin is widely implicated in processes related to tumor
development and progression due to its ability to inhibit
apoptosis, promote cell cycle progression, favor metastasis
and enhance angiogenesis [4]. While the connection
between survivin and angiogenesis has been extensively
documented, the evidence available so far largely points
towards survivin as an enhancer of endothelial cell viabil-
ity [13]. Here, we provide evidence highlighting a role for
survivin in angiogenesis by promoting VEGF expression
in tumor cells. Indeed, survivin expression was associated
with enhanced β-catenin/Tcf-Lef reporter activity via a
PI3K/Akt-dependent mechanism. As a consequence,
expression of several target genes including VEGF was en-
hanced and VEGF accumulated in the medium of tumor
cells. Consistent with the notion that survivin dependent
release of VEGF is relevant to tumor growth in vivo,
vascularization of tumors formed by cells with reduced
survivin levels was diminished. Moreover, conditioned
Figure 4 (See legend on next page.)
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Figure 4 Survivin effects on β-catenin protein levels and β-catenin/Tcf-Lef transcriptional activity were suppressed by inhibiting PI3K
or Akt in HEK293T cells. A,B: HEK293T cells (5×105) were seeded in 6-well plates and transfected with pEGFP-C1 or pEGFP-survivin (1.5 μg). After
transfection, cells were treated with LY294002 (20 μM) or wortmannin (10 nM). After 24 h, β-catenin, survivin, Akt, p-Akt, GFP and actin protein levels
were evaluated by western blotting. Protein levels were quantified by scanning densitometric analysis of western blots and normalized to actin. C:
HEK293T cells were seeded (5×105) in 6-wells plates and co-transfected with pcDNA or pcDNA-survivin (0.8 μg) and a dominant negative form (1 μg)
of Akt (AktM). After 24 h, β-catenin, survivin, Akt, p-Akt and GAPDH protein levels were evaluated by western blotting. Protein levels were quantified by
scanning densitometric analysis of western blots and normalized to GAPDH. D: HEK293T cells were seeded (5×105) in 6-wells plates and co-transfected
with pEGFP-C1 or pEGFP-survivin (1.5 μg) and the reporter plasmids pTOP-FLASH or pFOP-FLASH (1 μg). After transfection, cells were treated with
LY294002 (20 μM). Luciferase activity was obtained by calculating the pTOP-FLASH/pFOP-FLASH activity ratio for each condition. Data were previously
normalized to values for β-galactosidase activity. E: HEK293T cells were seeded (5×105) in 6-well plates and transiently cotransfected with pcDNA or
pcDNA-survivin (0.8 μg), the reporter plasmids pTOP-FLASH or pFOP-FLASH (1 μg) and in some cases dominant negative Akt (AktM, 1 μg). Luciferase
activity was obtained by calculating the pTOP-FLASH/pFOP-FLASH activity ratio for each condition. Data were previously normalized to values for
β-galactosidase activity. Numerical data shown are the means ± s.e.m. of results obtained in three independent experiments. Statistically significant
differences compared to mock controls are indicated (* p < 0.05).
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esis in a chick CAM assay and this effect was avoided using
VEGF neutralizing antibodies. Thus, survivin is shown here
for the first time to enhance VEGF expression in tumor
cells via a PI3K/Akt/β-catenin/Tcf-Lef-dependent mechan-
ism and to thereby promote angiogenesis.
Our previous studies revealed that CK2 promoted
tumor cell viabillity by enhancing β-catenin/Tcf-Lef-Figure 5 Survivin expression increased VEGF mRNA and VEGF protein
6-well plates and transfected with pEGFP-C1 or pEGFP-survivin (1.5 μ
were assessed by semi-quantitative RT-PCR. Actin was used as internal control.
was used as internal control. C,D Extracellular VEGF was determined by an ELIS
with pEGFP-C1 or pEGFP-survivin. Numerical data shown are the means ± s.e.m
independent experiments. Statistically significant differences compared to mocdependent expression of survivin. Moreover, these stud-
ies showed that overexpression of survivin alone was
sufficient to revert the detrimental effects of CK2 inhib-
ition on cell viability [36]. This was surprising since
many β-catenin/Tcf-Lef target genes were affected by
CK2 inhibition and suggested that survivin might
participate in a loop that feeds back again into the β-
catenin/Tcf-Lef pathway. Indeed, our results showed thatlevels in the medium: A,B: HEK293T cells (5×105) were seeded in
g). A: After 24 h, VEGF (VEGF165 and VEGF121) and survivin mRNA levels
B: Total VEGF mRNA levels were assessed by qPCR. Ribosomal 18S RNA
A assay of supernatants from HEK293T (C) or MKN45 cells (D) transfected
. of total VEGF measured in culture supernatants obtained in three
k controls are indicated (* P < 0.05).
Figure 6 Angiogenesis and VEGF expression were reduced in tumors derived from survivin-down regulated B16F10 cells: A,B: B16F10
cells stably transfected with shLUC or shSUR2 were used (see Figure 3). Cells (3 × 105) were subcutaneously injected in 8–10 week-old
C57BL6 mice (6 mice per treatment). Once the tumors reached a volume of approximately 1500mm3 mice were sacrificed, tumors extracted,
measured, divided in halves and formalin-fixed for 24 h. After that samples were paraffin-included, sectioned and then slices were de-paraffined
and hydrated. A: Samples were stained with arteta, which allows direct visualization of blood vessels. The left panel shows a representative section
of a tumor derived from shLUC transfected cells, the center panel, a tumor derived from shSUR2 transfected cells and the right panel, the quantification of
average blood vessel density (10 fields per mouse, total 60 fields, * p < 0.05). B: samples were analyzed by immunohistochemistry with anti-VEGF specific
antibodies. The left panel shows a representative section of a tumor derived from shLUC transfected cells, the center panel, a tumor derived from shSUR2
transfected cells and the right panel depicts the VEGF-Expression Level Score (ELS) obtained as described in Material & Methods for both conditions (10
samples each condition, * p < 0.05). Magnification bar = 100 μm.
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catenin protein levels and the expression of β-catenin-Tcf/
Lef target genes including COX2, and Survivin itself. Also,
downregulation of survivin B16F10 (mouse melanoma)
cells reduced cytoplasmic β-catenin, as well as β-catenin-
Tcf/Lef-dependent transcriptional activity (Figure 3).
Consistent with the notion that survivin did indeed
promote β-catenin/Tcf-Lef–dependent transcription, gen-
eric β-catenin/Tcf-Lef reporter activity, as well as activity
of a reporter specific for survivin itself increased upon
introducing survivin either alone or as a GFP-survivin
fusion protein (Figures 1C, D, F, H). Moreover, a DNA
microarray analysis revealed increases in the expression
of a considerable number of β-catenin-Tcf/lef dependent
genes (see Additional file 1: Supplementary information 1),
including genes involved in proliferation (Cyclin D1),
angiogenesis (VEGF), invasion (MMP-9) and metastasis(CD44). These findings illustrating global changes in
gene expression were confirmed in specific cases by RT-
PCR and qPCR, such as for Runx-2 and VEGF. Thus,
while previous reports in the literature indicate that sur-
vivin expression can promote the activation of many
signalling pathways [37] none of these have associated
survivin expression with enhanced transcription via
β-catenin-Tcf/lef, as documented by the experiments
shown here.
Survivin is overexpressed in essentially all human can-
cer cells and expression has not only been associated
with the acquisition of several of the so-called tumor cell
traits, as defined by Hanahan and Weinberg [38,39], but
also with maintenance of tumor cell viability in vitro and
in vivo. The ability of survivin to do so is often linked to
interactions with other proteins and the formation of
multi-protein complexes that control proliferation and
Figure 7 Survivin expression augmented VEGF-dependent angiogenesis in the chick-CAM assay: A,B: HEK293T cells (2×106) were
seeded in 60 mm plates, transfected with pEGFP-C1 or pEGFP-survivin (5μg) and after 48 h supernatants were collected and
centrifuged. Also, cells in suspension were obtained (106/mL). The solutions, fresh medium alone, or media obtained from non-transfected cells or cells
in suspension, were pipetted onto chick chorioallantoic membranes (CAM) as described in Materials and Methods. Per condition 3 eggs were employed.
A week later CAMs were fixed and stained with hematoxilin-eosin. Three sections per egg were analyzed. A: Vessels (arrows) were photographed and
counted (10 photographs per section). B: The number of vessels per mm2 optic field (mean ± s.e.m., n = 3, *: p < 0.05) are depicted. C: Supernatants of
pEGFP-C1 and pEGFP-survivin obtained as described (A,B), were treated with increasing concentrations of anti-VEGF neutralizing antibodies (0.1, 1, 10
μg/mL). As an IgG control, anti-β3 integrin was used at the highest concentration (10 μg/mL). Numerical data shown are the means ± s.e.m. of results
obtained in three independent experiments. Statistically significant differences compared to mock controls are indicated (* = p < 0.05). D: Model: β-
catenin translocates to the nucleus where it binds Tcf/Lef and induces the expression of target genes (survivin, vegf, cox-2 are depicted). Survivin
(by unknown mechanisms) favors PI3K/Akt activation, which increases β-catenin-Tcf/Lef transcriptional activity, thereby promoting its own expression
(feeding this positive feedback loop), as well as that of cox-2 and vegf. The protein VEGF is secreted to the extracellular compartment where it
induces angiogenesis.
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also shown to enhance the metastatic potential of cancer
cells by promoting, together with XIAP, NF-kB-
dependent transcription and secretion of fibronectin
[11]. Hence, these observations provide a more general
framework to understanding why survivin expression is
augmented in so many different types of human cancers
and why expression in those cells is so important for
tumor cell survival.
Previously, COX2 was shown to participate in a feed-
forward amplification loop involving β-catenin/Tcf-Lef-
dependent transcription by generating PGE2, which
stimulated EP receptors and favored inactivation of themulti-protein complex that promotes β-catenin degrad-
ation [31]. In doing so, a target gene of β-catenin/Tcf-
Lef was shown to enhance signaling via the Wnt
pathway in a manner involving PI3K/Akt. This we con-
sidered an interesting point since a large number of pre-
vious studies established a tight relationship between
PI3K/Akt and survivin. For instance, activation of the
PI3K/Akt pathway favors survivin expression by enhan-
cing NF-kB transcriptional activity [41]. Furthermore,
PI3K/Akt also enhances β-catenin-Tcf/lef-dependent
transcription by stabilizing β-catenin, either by inhibiting
GSK-3β or by directly phosphorylating β-catenin, which
favors translocation to the nucleus [42,43]. Thus, if
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via PI3K/Akt signaling, an amplification loop that greatly
favors tumor cell survival would be the consequence. An
initial screen with inhibitors pointed towards PI3K activa-
tion as being key to EGFP-survivin-enhanced expression of
endogenous survivin (see Additional file 1: Supplementary
information 3). Additional experiments using another
PI3K inhibitor and over-expression of a dominant negative
Akt construct (AktM) indicated that inhibition of this
pathway ablated survivin-induced β-catenin stabilization
and activation of reporter constructs (Figure 4). Thus,
although we cannot completely exclude alternative in-
terpretations, the results presented here point towards
the existence of a survivin-PI3K/Akt connection, and
most importantly, identify this connection as part of a
survivin-mediated tumor cell survival strategy that
harnesses β-catenin-Tcf/lef-dependent transcription in
the process (see summary Figure 7D).
The fact that PI3K/Akt signalling and survivin are so
tightly linked may not come as a surprise, since all are im-
plicated in events that favor cell survival and proliferation.
However, the novelty of our current findings resides in
showing that the ability of survivin to promote β-catenin/
Tcf-Lef-dependent transcription requires PI3K/Akt. How
exactly survivin impacts on PI3K/Akt signalling is a ques-
tion of considerable interest. Survivin is generally thought
to modulate cellular processes via specific binding part-
ners. For instance, survivin is implicated in the control of
apoptosis by binding to several partners, including XIAP,
SMAC-DIABLO, AIF and HBXIP (see introduction).
Interestingly, survivin binding to HBXIP together with
HBX, reportedly activates PI3K in several cell models.
Whether this particular multiprotein survivin complex or
others that remain to be discovered are involved in the
events we describe here is an intriguing question that
needs to be addressed in future experiments.
Angiogenesis is important for clinical progression of
disease and patient survival. Moreover, pharmacological
targeting of angiogenesis is an effective approach
employed in cancer treatment [44]. The process of
tumor vascularization is essential to allow solid tumors
to grow beyond a minimal size and it has been sug-
gested that the ability of a tumor cell to produce and
secrete VEGF is crucial and involves several steps: 1)
The liberation of pro-angiogenic factors from tumor
cells, including VEGF; 2) Changes in the morphology of
endotheliocytes; 3) Liberation of proteolytic enzymes
that degrade the basal lamina; 4) Migration and forma-
tion of tubular structures; 5) Proliferation of endothe-
liocytes and 6) Differentiation into capillaries [2]. As
mentioned, VEGF is important in this sequence because
it participates in most steps, except the first, by acting
on tyrosine kinase receptors of the VEGFR family
(VEGFR1 and VEGFR2). Upon activation, VEGFR1 andVEGFR2 promote survival and proliferation, as well as in-
hibit apoptosis of endothelial cells [3], all known functions
of survivin. Consistent with this paradigm, survivin has
thus far largely been attributed a role in angiogenesis as a
participant downstream of VEGFR signalling (see intro-
duction). In this study, we specifically provide evidence
indicative of a novel role for survivin in promoting the
production of VEGF in tumor cells via a mechanism
involving PI3K/Akt (see Figure 7D).
Conclusions
We describe here for the first time that survivin enhances
the expression of a considerable number of genes by
augmenting β-catenin-Tcf/Lef transcriptional activity. This
is achieved in a manner dependent on PI3K/Akt signalling
in the same cells. In doing so, survivin contributes to the
formation of a positive feedback circuit in which survivin
increases β-catenin-Tcf/Lef transcriptional activity and
this in turn favors expression of target genes and the ac-
quisition of traits commonly associated with tumor devel-
opment, survival and progression. Growth of solid tumors
requires angiogenesis and survivin has been implicated in
this process largely as an element that functions down-
stream of VEGFR signalling. Our current studies show
that survivin induces VEGF transcription, expression and
accumulation in conditioned media and favors angiogen-
esis in a VEGF-dependent manner (see Figure 7D).
Methods
Materials
Monoclonal anti β-catenin and anti-COX-2 antibodies were
from Transduction Laboratories (Lexington, KY). Rabbit
polyclonal anti-human survivin and anti-actin antibodies
were from R&D Systems (Minneapolis, MN) and Sigma
(St. Louis, MO), respectively. Polyclonal rabbit anti-
GFP and anti-Cyclin D1 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Polyclonal anti-Akt,
anti-p-Akt, and monoclonal anti-GAPDH were from Cell
Signaling. Monoclonal anti-VEGF antibody was from
R&D Systems. Goat anti-rabbit IgG and anti-mouse IgG
antibodies coupled to horseradish peroxidase (HRP) were
from Bio-Rad Laboratories (Hercules, CA) and Sigma, re-
spectively. EZ-ECL Chemiluminescence Substrate was
from Biological Industries (Kibbutz Beit Haemek, Israel).
Superfect Reagent and the Plasmid Midi Kit were from
Qiagen (Valencia, CA). TriZOL reagent was from Invitrogen
(Carlsbad, CA). AMV reverse transcriptase (AMV RT)
and Taq DNA polymerase were from Promega (Madison,
WI). Cell medium and antibiotics were from Invitrogen-
BRL (Paisley, Scotland, United Kingdom). Fetal bovine
serum (FBS) was from Hyclone (Logan, UT). Luciferin
was purchased from United States Biological (Swamps-
cott, MA). Inhibitors SB-216763 and wortmannin were
purchased from Sigma and the inhibitor 2-morpholin-4-
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(San Diego, CA).
Cell culture and transfections
HEK293T and NIH3T3 cells were cultured in DMEM,
MKN-45 and B16-F10 cells in RPMI medium. In all cases
media were supplemented with 10% FBS and antibiotics
(10,000 U/ml penicillin and 10 mg/ml streptomycin).
HEK293T, NIH3T3, MKN-45 and B16-F10 were trans-
fected with Lipofectamine 2000 according to the manufac-
turer’s instructions. After 3 h, the medium was diluted
with 1 mL of medium together with inhibitors when used.
Transfection efficiency was checked by epifluorescence
microscopy 24 h after transfection. Cells were then har-
vested, centrifuged and stored at −80°C.
Western blotting
Cell extracts were prepared as previously described [45],
separated (50–80 μg total protein per lane) by SDS-PAGE
on 12% acrylamide minigels (Bio-Rad Laboratories), and
transferred to nitrocellulose as described previously [46].
Blots were blocked with 5% milk in 0.1% Tween-TBS and
then probed with anti-β-actin (1:5000), anti-COX-2
(1:500), anti-β-catenin (1:1000), anti-Cyclin D1 (1:2000),
anti Akt (1:1000), anti p-Akt (1:1000), anti-GAPDH
(1:2000) or anti-survivin (1:3000) antibodies. Bound anti-
bodies were detected with HRP-conjugated secondary
antibodies and the EZ-ECL system.
Reporter assays
For β-catenin-Tcf/Lef and survivin promoter reporter as-
says HEK293T, NIH3T3, MKN-45 and B16F10 cells were
transfected with 1 μg of each plasmid: pTOP-FLASH
(Tcf/Lef reporter), pFOP-FLASH (mutated Tcf/Lef bind-
ing site), pLuc-1710 (survivin promoter) or pLuc420–3M
(mutated Tcf/Lef binding site). After transfection (24 h),
cells were lysed, luciferase activity was quantified and
standardized as described previously [33].
Analysis of mRNA: RT-PCR and qPCR
RT-PCR
Total RNA was isolated with TriZOL™ following instruc-
tions provided by manufacturer. RNA samples were
spectrophotometrically quantified, characterized by elec-
trophoresis in 1% agarose gels and then used as tem-
plates to generate cDNA under standard conditions in
the presence of DNAase to eliminate any traces of gen-
omic DNA. Specific PCR products were generated using
the following primers: COX-2: sense primer 5′-TTCA
AATGAGATTGTGGGAAAATTGCT-3′ and anti-sense
primer 5′-AGATCATCTCTGCCTGAGTATCTT-3′; sur-
vivin: sense primer 5′-CCGACGTTGCCCCCTGC-3′ and
anti-sense primer 5′-TCGATGGCACGGCGCAC-3′; Runx-2:
sense primer 5′-CAGTTCCCAAGCATTTCATCC-3′ andanti-sense primer 5′-TCAATATGGTCGCCAAACAG-3′;
Cyclin D1: sense primer 5′-ACCTGAGGAGCCCCAAC
AA-3′ and anti-sense primer 5′-TCTGCTCCTGGCAG
GCC-3′; VEGF: sense primer 5′-AGGCCAGCACATAG-
GAGAGA-3′ and antisense primer 5′-ACCGCCTCGGC
TTGTCACAT-3′; actin: sense primer 5′-AAATCGTGCG
TGACATTAAGC-3′ and anti-sense primer, 5′-CCGATC-
CACACGGAGTACTT-3′; and 18S rRNA housekeeping
gene: sense primer 5′-TCAAGAACGAAAGTCGGAGG-
3′ and anti-sense primer 5′-GGACATCTAAGGGCAT-
CACA-3′.
All reaction products were analyzed after 25–30 amplifi-
cation cycles, each of which involved consecutive 1-min
steps at 94, 55–60, and 72°C. Survivin and COX-2 levels
were normalized to actin RNA in semi-quantitative RT-
PCR studies.
Real-Time quantitative PCR
The results obtained by semi-quantitative studies were
confirmed by real-time quantitative PCR (qPCR) analysis
with the brilliant SYBR green qPCR kit (Stratagene, La
Jolla, CA). The PCR reactions were carried out using a
Chromo-4 real-time PCR detection system (Bio-Rad
Laboratories) and thermo cycler conditions following
suggestions of the manufacturer. The relative gene expres-
sion levels were calculated using the 2ΔΔCT method [47].
COX-2, Runx-2 and VEGF levels were normalized to
RNA of the 18S rRNA housekeeping gene. All data were
expressed relative to values obtained for mock-transfected
cells (value = 1).
shRNA knock-down of survivin expression
B16F10 cells
The oligonucleotide containing shRNA candidates for
mouse survivin #1,GAAGAACTAACCGTCAGTGAA and
#2, CCTACCGAGAACGAGCCTGAT or control shRNA
for Luciferase CGCTGAGTACTTCGAAATGTC were
prepared as previously described [48]. Post-transfection (48
h), media containing lentivirus were filtered through a 0.45
μm pore and used to transduce B16F10 cells in the pres-
ence of 8 μg/ml polybreen. After 24 h cells were selected
with puromycin (2μg/ml) for seven days and expression
was monitored by Western blotting. Plasmids encoding the
envelope protein VSV-γ (pHCMV-G), the packaging plas-
mid pΔ8.9 (pCMVΔR8.9) and pLKO.1 plasmids containing
shRNA for survivin and control plasmid containing shRNA
for Luciferase (shLuc) were provided by Dr. Claudio Hetz
(Universidad de Chile, Santiago, Chile).
Quantification of VEGF levels
VEGF extracellular protein levels were determined in
supernatants from transfected HEK293T or MKN-45
cells. Supernatants were evaluated using the Quantikine
VEGF-ELISA assay (R&D Systems).
Fernández et al. Molecular Cancer 2014, 13:209 Page 13 of 15
http://www.molecular-cancer.com/content/13/1/209Mouse melanoma tumor angiogenesis model
C57BL6 8–12 week-old female mice were used. They were
obtained from Instituto de Salud Pública and were kept in
the animal facility (Bioterio) of the Faculty of Medicine
(University of Chile). Protocols to work with these animals
were approved by local bioethical committee (University
of Chile, Faculty of Medicine) in 2008 for the FONDECYT
(National Chilean research agency) research project
(#1090071) of Dr. Andrew Quest. Mice (12 animals total,
6 animals per group) were subcutaneously injected with
300.000 B16F10 cells. Roughly two weeks after the injec-
tion palpable tumors became detectable and were mea-
sured daily. When tumors reached the ethically permitted
maximum (2500mm3), mice were sacrificed. Tumors were
extracted, divided and then fixed in 10% buffered formalin.
After 48 h in fixation solution, they were processed to ob-
tain sections of 5 μm and microvessel density or VEGF
were evaluated. Microvessel density quantification: Sam-
ples were stained with arteta to improve endotheliocyte
visualisation and blood vessels were counted by a trained
technician who was unaware of sample identity as de-
scribed previously [49]. VEGF detection: Histological
sections were treated with 3% Peroxide Hydrogen in
methanol for 10 minutes and incubated for 30 minutes in
Dako Target Retrieval (Dako, CA). After washing with
PBS, sections were incubated with Anti-VEGF165 Poly-
clonal Antibody (Millipore™, 1:100), developed according
to instructions provided with the Histomouse MAX-AEC
Broad Spectrum™ Kit (Invitrogen, Camarillo, CA), coun-
terstained with Haematoxylin and mounted with Clear-
mount™ (Invitrogen). Using identical microscope and
camera settings, five digital images per sample were taken
to accurately reflect the overall staining. Immunochemical
staining for VEGF from all images was analyzed using the
commercially available Image-Pro Plus v. 4.5.029 software
(Media Cybernetics, USA). A color file was created that
exactly selected the hue, saturation and intensity reflecting
protein expression levels. This color file defined the range
of the signal and was applied to all samples. The Expres-
sion Level Score (ELS%) was determined based on the
Mean Density of VEGF-specific staining, defined by the
color file, per area evaluated.
Chick-CAM assay
Fertilized eggs from White Legorn hens (Gallus gallus)
were used as described previously [50], all protocols ap-
proved by the local ethics committee as stated prviously.
Eggs were purchased from the Public Health Institute of
Chile, incubated in animals facility of the Faculty of
Medicine at 25°C for 24 h, marked at the embryonic
pole (apex) and incubated at 37°C for another 72 h.
Then a small hole (1 mm) was drilled into the acute
pole to extract albumin and thereby avoid adherence of
the embryo to the upper cortex. Subsequently, a largeropening (2×1 cm) was created at the embryonic pole and
sealed with Saran-wrap. A week later, the plastic cover was
removed and a 5 mm diameter methylcellulose filter was
placed on the chorioallantoic membrane, and 10 μL of
sample (media with or without cells) was added to the fil-
ter. Samples included either 3×104 HEK293T cells (trans-
fected with survivin 48 h before the experiment) or
supernatants from the same transfected cells. In neutraliz-
ing experiments, either anti-VEGF or anti-β1-integrin anti-
bodies were added and mixed with the media 20 min
before application to the filters. After 3 days, CAMs
were removed from the eggs, fixed in 4% p-formaldehyde,
then dehydrated, paraffin embedded and stained with
hematoxilin-eosin. Blood vessels were counted manually
by a trained technician who was unaware of sample
identities.
Statistical analysis
Results were statistically compared using paired student’s
t test. All data were from 3 or more independent experi-
ments. p values (two-tailed) < 0.05, was considered
significant.
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